Omada Health's (NASDAQ:OMDA - Get Free Report) quiet period is set to end on Wednesday, July 16th. Omada Health had issued 7,900,000 shares in its public offering on June 6th. The total size of the offering was $150,100,000 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on OMDA shares. The Goldman Sachs Group started coverage on shares of Omada Health in a research note on Tuesday, July 1st. They issued a "buy" rating and a $29.00 price target on the stock. Needham & Company LLC assumed coverage on shares of Omada Health in a report on Tuesday, July 1st. They issued a "buy" rating and a $23.00 target price on the stock. Morgan Stanley started coverage on Omada Health in a report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target for the company. Evercore ISI raised their price target on shares of Omada Health from $21.00 to $23.00 and gave the company an "outperform" rating in a research note on Wednesday. Finally, Wall Street Zen upgraded shares of Omada Health to a "hold" rating in a report on Monday, June 16th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $23.86.
Read Our Latest Stock Report on Omada Health
Omada Health Stock Up 6.4%
OMDA traded up $1.07 during trading on Thursday, reaching $17.92. 695,683 shares of the stock traded hands, compared to its average volume of 682,274. Omada Health has a 12 month low of $14.14 and a 12 month high of $28.40.
About Omada Health
(
Get Free Report)
Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
Further Reading
Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.